Literature DB >> 11809769

Identification of novel non-phosphorylated ligands, which bind selectively to the SH2 domain of Grb7.

Stephanie C Pero1, Lyn Oligino, Roger J Daly, Amy L Soden, Chen Liu, Peter P Roller, Peng Li, David N Krag.   

Abstract

Grb7 is an adapter-type signaling protein, which is recruited via its SH2 domain to a variety of receptor tyrosine kinases (RTKs), including ErbB2 and ErbB3. It is overexpressed in breast, esophageal, and gastric cancers, and may contribute to the invasive potential of cancer cells. Molecular interactions involving Grb7 therefore provide attractive targets for therapeutic intervention. We have utilized phage display random peptide libraries as a source of small peptide ligands to the SH2 domain of Grb7. Screening these libraries against purified Grb7 SH2 resulted in the identification of Grb7-binding peptide phage clones that contained a non-phosphorylated Tyr-X-Asn (YXN) motif. The tyrosine-phosphorylated form of this motif is characteristic of Grb7 SH2 domain binding sites identified in RTKs and other signaling proteins such as Shc. Peptides that are non-phosphorylated have greater potential in the development of therapeutics because of the instability of a phosphate group in vivo. Using a biased library approach with this conserved YXN motif, we identified seven different peptide phage clones, which bind specifically to the SH2 domain of Grb7. These peptides did not bind to the SH2 domain of Grb2 (which also selects for Asn at pY(+2)) or Grb14, a closely related family member. The cyclic structure of the peptides was required to bind to the Grb7 SH2 domain. Importantly, the synthetic Grb7-binding peptide G7-18 in cell lysates was able to specifically inhibit the association of Grb7 with the ErbB family of RTKs, in particular ErbB3, in a dose-dependent manner. These peptides will be useful in the development of targeted molecular therapeutics for cancers overexpressing Grb7 and in the development of Grb7-specific inhibitors to gain a complete understanding of the physiological role of Grb7.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11809769     DOI: 10.1074/jbc.M111816200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

Review 1.  The intertwining of structure and function: proposed helix-swapping of the SH2 domain of Grb7, a regulatory protein implicated in cancer progression and inflammation.

Authors:  Sally Pias; Tabitha A Peterson; Dennis L Johnson; Barbara A Lyons
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

2.  Preparation and crystallization of the Grb7 SH2 domain in complex with the G7-18NATE nonphosphorylated cyclic inhibitor peptide.

Authors:  Min Y Yap; Matthew C J Wilce; Daniel J Clayton; Patrick Perlmutter; Marie-Isabel Aguilar; Jacqueline A Wilce
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-11-26

3.  Activating mutations and/or expression levels of tyrosine kinase receptors GRB7, RAS, and BRAF in testicular germ cell tumors.

Authors:  Alan McIntyre; Brenda Summersgill; Hayley E Spendlove; Robert Huddart; Richard Houlston; Janet Shipley
Journal:  Neoplasia       Date:  2005-12       Impact factor: 5.715

4.  Receptor protein-tyrosine phosphatase α regulates focal adhesion kinase phosphorylation and ErbB2 oncoprotein-mediated mammary epithelial cell motility.

Authors:  Benoit Boivin; Fauzia Chaudhary; Bryan C Dickinson; Aftabul Haque; Stephanie C Pero; Christopher J Chang; Nicholas K Tonks
Journal:  J Biol Chem       Date:  2013-11-11       Impact factor: 5.157

5.  Potential of phage-displayed peptide library technology to identify functional targeting peptides.

Authors:  Lauren Rh Krumpe; Toshiyuki Mori
Journal:  Expert Opin Drug Discov       Date:  2007-04       Impact factor: 6.098

6.  Preparation of crystals for characterizing the Grb7 SH2 domain before and after complex formation with a bicyclic peptide antagonist.

Authors:  Nigus D Ambaye; Menachem J Gunzburg; Daouda A K Traore; Mark P Del Borgo; Patrick Perlmutter; Matthew C J Wilce; Jacqueline A Wilce
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2014-01-21       Impact factor: 1.056

Review 7.  Phosphotyrosine isosteres: past, present and future.

Authors:  Robert A Cerulli; Joshua A Kritzer
Journal:  Org Biomol Chem       Date:  2019-11-28       Impact factor: 3.876

Review 8.  Targeting SH2 domains in breast cancer.

Authors:  Pietro Morlacchi; Fredika M Robertson; Jim Klostergaard; John S McMurray
Journal:  Future Med Chem       Date:  2014       Impact factor: 3.808

9.  Grb7 gene amplification and protein expression by FISH and IHC in ovarian cancer.

Authors:  Manman Zeng; Zhu Yang; Xiaoyu Hu; Yi Liu; Xiaotao Yang; Hailong Ran; Yanan Li; Xu Li; Qiubo Yu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

10.  Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.

Authors:  Alessio Nencioni; Michele Cea; Anna Garuti; Mario Passalacqua; Lizzia Raffaghello; Debora Soncini; Eva Moran; Gabriele Zoppoli; Vito Pistoia; Franco Patrone; Alberto Ballestrero
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.